Acetyl-UBA52/RPS27A/UBB/UBC (K29) Antibody

What is the Acetyl-UBA52/RPS27A/UBB/UBC (K29) Antibody and what epitope does it recognize?

The Acetyl-UBA52/RPS27A/UBB/UBC (K29) Antibody is a rabbit polyclonal antibody specifically designed to recognize the acetylation of lysine 29 (K29) in ubiquitin proteins encoded by the UBA52, RPS27A, UBB, and UBC genes. This antibody is generated using a synthesized peptide derived from human ubiquitin surrounding the K29 acetylation site . The antibody has been affinity-purified from rabbit antiserum using epitope-specific immunogen to ensure high specificity . It recognizes the post-translational modification of acetylation at the K29 position, which plays crucial roles in regulating protein function and cellular pathways.

What species reactivity does the antibody demonstrate?

The Acetyl-UBA52/RPS27A/UBB/UBC (K29) Antibody demonstrates consistent cross-reactivity across multiple mammalian species:

This multi-species reactivity is confirmed across multiple sources , making the antibody suitable for comparative studies across these mammalian models. The conservation of reactivity indicates that the K29 acetylation site and surrounding epitope sequence are highly conserved across these species, suggesting evolutionary importance of this post-translational modification.

What are the recommended applications for this antibody?

The antibody has been validated for specific research applications with optimized dilution parameters:

These applications have been specifically tested and optimized . The significant difference in dilution ratios between ELISA and Western Blot highlights the importance of application-specific optimization. For Western Blot applications, researchers should note that validation has been demonstrated using HepG2 cells as shown in product images .

How does acetylation at K29 functionally impact the ubiquitin system compared to other lysine modifications?

Acetylation at the K29 position of ubiquitin proteins represents a critical regulatory mechanism that intersects with the ubiquitin-proteasome pathway. While ubiquitination typically targets proteins for degradation, acetylation at K29 can modulate this process by competing with ubiquitination sites, potentially protecting proteins from degradation . Research indicates that K29 acetylation in UBA52, RPS27A, UBB, and UBC has been implicated in regulating protein degradation, DNA repair mechanisms, and cell cycle progression .

Unlike other common ubiquitin modifications (such as K48 and K63 linkages that signal for proteasomal degradation and DNA repair respectively), K29 acetylation represents a distinct regulatory layer that can functionally antagonize ubiquitination. This creates a sophisticated regulatory circuit where acetylation and ubiquitination at the same residue can have opposing biological outcomes, allowing for fine-tuned control of protein stability and function in response to cellular conditions.

What experimental controls should be implemented when using this antibody to study protein acetylation dynamics?

When designing experiments to study protein acetylation dynamics with this antibody, researchers should implement a comprehensive set of controls:

• Acetylation inhibitor controls: Include samples treated with histone deacetylase inhibitors (e.g., trichostatin A, nicotinamide) to increase acetylation levels as positive controls.

• Deacetylation treatment controls: Conversely, treat samples with recombinant deacetylases to reduce acetylation signals as negative controls.

• Competing peptide assay: Pre-incubate the antibody with excess acetylated K29 peptide before immunostaining to validate signal specificity.

• Non-acetylatable mutants: Express K29R mutant versions of the target proteins, which cannot be acetylated, to confirm antibody specificity.

• Cell-type specificity controls: Given the antibody's reactivity across human, mouse, and rat samples , include different cell types to assess tissue-specific patterns of K29 acetylation.

These methodological controls allow for rigorous validation of acetylation signals and enable accurate interpretation of experimental results when studying dynamic changes in protein acetylation levels.

How can researchers differentiate between acetylation signals from different ubiquitin gene products (UBA52, RPS27A, UBB, UBC) using this antibody?

Differentiating between acetylation signals from distinct ubiquitin gene products presents a methodological challenge since the antibody recognizes the conserved K29 acetylation site across all four proteins. To address this experimental limitation, researchers should employ a layered approach:

• Sequential immunoprecipitation: Perform initial immunoprecipitation with gene-specific antibodies against UBA52, RPS27A, UBB, or UBC, followed by Western blot with the K29 acetylation antibody .

• Size-based separation: Leverage the different molecular weights of these proteins (especially the fusion proteins UBA52 and RPS27A which include ribosomal proteins) through high-resolution gel electrophoresis prior to Western blotting .

• Genetic approaches: Use siRNA knockdown or CRISPR-based knockout of individual ubiquitin genes to determine contribution to the total K29 acetylation signal.

• Mass spectrometry validation: Employ targeted mass spectrometry with isotopically labeled peptides to quantitatively distinguish acetylation signals from each gene product.

This multi-technique approach enables researchers to deconvolute the complex signal pattern and attribute acetylation events to specific ubiquitin gene products despite using a single antibody that recognizes the conserved modification site.

What are the optimal sample preparation protocols for detecting K29 acetylation in different experimental contexts?

Optimal detection of K29 acetylation requires careful consideration of sample preparation protocols tailored to experimental objectives:

• Cell lysate preparation:

  • Use freshly prepared lysis buffer containing deacetylase inhibitors (5-10 mM nicotinamide, 1-2 μM trichostatin A)

  • Include protease inhibitors to prevent protein degradation

  • Maintain cold temperatures (4°C) throughout processing to preserve acetylation marks

• Tissue sample processing:

  • Flash-freeze tissues in liquid nitrogen immediately after collection

  • Homogenize in acetylation-preserving buffers containing HDAC inhibitors

  • Consider using phosphatase inhibitors to prevent cross-talk between phosphorylation and acetylation

• Protein extraction optimization:

  • For nuclear proteins: use gentle nuclear extraction buffers with low detergent concentrations

  • For cytoplasmic proteins: avoid harsh detergents that may disrupt protein interactions

• Western blot considerations:

  • Use recommended antibody dilutions of 1:500-1:2000

  • Include positive controls such as HepG2 cell lysates which have demonstrated clear signals

  • Block with 5% BSA rather than milk (milk contains deacetylases)

These methodological considerations ensure optimal preservation and detection of K29 acetylation while minimizing experimental artifacts that could confound data interpretation.

How should researchers troubleshoot weak or non-specific signals when using this antibody?

When encountering signal issues with the Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibody, implement this systematic troubleshooting approach:

• For weak signals:

  • Increase antibody concentration (start at 1:500 dilution for Western blot)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Increase protein loading (50-100 μg of total protein)

  • Use enhanced chemiluminescence detection systems with longer exposure times

  • Pretreat samples with deacetylase inhibitors to preserve acetylation marks

• For non-specific signals:

  • Increase blocking time and concentration (5% BSA for 2 hours)

  • Perform more stringent washing steps (5 washes of 10 minutes each)

  • Use freshly prepared antibody dilutions to prevent aggregation

  • Validate specificity with peptide competition assays

  • Decrease secondary antibody concentration to reduce background

• Quality control validation:

  • Test antibody with recommended positive control (HepG2 cells)

  • Implement appropriate storage conditions (store at -20°C or -80°C, avoid repeated freezing/thawing)

  • Check antibody viability with known positive samples before experimental use

This methodical approach helps researchers identify and address specific experimental variables affecting antibody performance, ensuring reliable and reproducible results.

How can this antibody be employed to study the relationship between ubiquitination and acetylation in disease models?

The Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibody provides a powerful tool for investigating the interplay between ubiquitination and acetylation in disease contexts:

• Cancer research applications:

  • Evaluate K29 acetylation levels across tumor progression stages to identify correlations with disease advancement

  • Compare acetylation patterns between treatment-resistant and treatment-sensitive cancer cell lines

  • Investigate how oncogenic signaling pathways modulate the balance between K29 acetylation and ubiquitination

• Neurodegenerative disease models:

  • Examine K29 acetylation in protein aggregation models (Alzheimer's, Parkinson's, Huntington's disease)

  • Track temporal changes in K29 acetylation during disease progression in animal models

  • Assess how disease-associated mutations affect K29 acetylation dynamics

• Metabolic syndrome investigations:

  • Analyze K29 acetylation changes in response to metabolic stress conditions

  • Evaluate tissue-specific differences in K29 acetylation between healthy and diabetic/obese models

  • Determine how dietary interventions influence K29 acetylation patterns

• Dual-detection methodologies:

  • Combine the K29 acetylation antibody with ubiquitin linkage-specific antibodies to simultaneously assess both modifications

  • Implement sequential immunoprecipitation to isolate proteins modified by both acetylation and ubiquitination

  • Use proximity ligation assays to visualize co-occurrence of acetylation and ubiquitination in situ

These research applications leverage the antibody's specificity for K29 acetylation to illuminate how this modification intersects with ubiquitination in pathological contexts, potentially revealing novel therapeutic targets .

What experimental designs can effectively assess the dynamics of K29 acetylation in response to cellular stress?

To investigate the temporal dynamics of K29 acetylation during cellular stress responses, researchers should implement these experimental designs:

• Time-course analyses:

  • Subject cells to stressors (oxidative, ER, genotoxic, or metabolic stress) and collect samples at defined intervals

  • Perform Western blot analysis using the Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibody at 1:500-1:2000 dilution

  • Quantify band intensities normalized to total protein or housekeeping controls

  • Plot acetylation changes against time to establish temporal profiles

• Pharmacological interventions:

  • Pretreat cells with acetyltransferase inhibitors before stress induction

  • Compare stress-induced acetylation with and without deacetylase inhibitors

  • Assess recovery dynamics by removing stressors and tracking acetylation reversion

• Genetic manipulation approaches:

  • Generate cells expressing acetylation-mimetic (K29Q) or acetylation-deficient (K29R) mutants

  • Compare stress tolerance between wild-type and mutant cells

  • Measure downstream stress response pathway activation in each genetic background

• Live-cell imaging methodologies:

  • Develop fluorescent biosensors incorporating the epitope recognized by the antibody

  • Perform real-time imaging during stress induction to capture rapid acetylation dynamics

  • Correlate acetylation changes with cellular stress response markers

• Multi-omics integration:

  • Combine K29 acetylation Western blots with proteomic profiling of the acetylome

  • Correlate transcriptomic changes with K29 acetylation dynamics

  • Integrate metabolomic data to connect metabolic state with acetylation patterns

These experimental designs enable comprehensive characterization of how K29 acetylation responds to cellular stress, potentially revealing this modification as an important regulatory node in stress adaptation mechanisms.

How might emerging technologies enhance the study of K29 acetylation beyond current antibody-based methods?

The study of K29 acetylation stands to be revolutionized by emerging technologies that complement traditional antibody-based detection:

• Advanced mass spectrometry approaches:

  • Targeted parallel reaction monitoring (PRM) mass spectrometry for quantitative profiling of K29 acetylation across the proteome

  • Top-down proteomics to analyze intact proteins with multiple post-translational modifications

  • Crosslinking mass spectrometry to identify interaction partners specific to K29-acetylated proteins

• CRISPR-based technologies:

  • CRISPR activation/inhibition systems targeting acetyltransferases and deacetylases that regulate K29 acetylation

  • Base editing to generate precise K29 mutations in endogenous genes

  • CRISPR screens to identify novel regulators of K29 acetylation

• Proximity labeling methodologies:

  • TurboID or APEX2 fusion proteins to identify the interactome of K29-acetylated proteins

  • Spatially-resolved proximity labeling to map subcellular localization of K29 acetylation events

  • Temporal control of proximity labeling to capture dynamic interaction changes

• Structural biology integration:

  • Cryo-EM studies of protein complexes containing K29-acetylated ubiquitin

  • NMR analysis of structural changes induced by K29 acetylation

  • Molecular dynamics simulations to predict functional impacts of K29 acetylation

• Single-cell technologies:

  • Development of single-cell proteomics methods to detect K29 acetylation heterogeneity

  • Integration with single-cell transcriptomics to correlate acetylation with gene expression profiles

  • Spatial proteomics to map tissue distribution of K29 acetylation patterns

These technological advances will propel K29 acetylation research beyond the limitations of antibody-based detection, providing deeper insights into its biological functions and regulatory mechanisms.

What are the potential therapeutic implications of targeting K29 acetylation in disease contexts?

Research into K29 acetylation reveals promising therapeutic avenues across multiple disease contexts:

• Cancer therapeutic strategies:

  • Develop small molecule inhibitors targeting enzymes mediating K29 acetylation/deacetylation

  • Design peptide-based therapeutics that mimic or block K29 acetylation interactions

  • Explore synergistic effects between proteasome inhibitors and K29 acetylation modulators

• Neurodegenerative disease interventions:

  • Target K29 acetylation to modulate protein aggregation processes

  • Investigate neuroprotective effects of maintained K29 acetylation levels

  • Develop biomarkers based on K29 acetylation patterns for early disease detection

• Metabolic disorder approaches:

  • Manipulate K29 acetylation to influence metabolic enzyme activity

  • Target tissue-specific K29 acetylation patterns to address localized metabolic dysfunction

  • Develop dietary interventions that normalize disrupted K29 acetylation profiles

• Inflammatory condition treatments:

  • Modulate K29 acetylation to influence NF-κB signaling and inflammatory responses

  • Target acetylation-dependent protein interactions in immune cells

  • Develop combination therapies targeting both acetylation and ubiquitination pathways

• Translational research considerations:

  • Establish K29 acetylation profiles as diagnostic or prognostic biomarkers

  • Develop companion diagnostics using the Acetyl-UBA52/RPS27A/UBB/UBC (K29) antibody

  • Investigate patient-specific variations in K29 acetylation for personalized medicine approaches

The therapeutic potential of targeting K29 acetylation stems from its involvement in fundamental cellular processes and disease-associated dysregulation , opening avenues for novel interventions that could address unmet clinical needs across multiple pathologies.